Want to see ICUI full AI Analyst Report?
ICUI Stock Chart & Stats
$151.65
-$2.36(-1.46%)
At close: 4:00 PM EST
$151.65
-$2.36(-1.46%)
Day’s Range― - ―
52-Week Range$107.00 - $162.18
Previous CloseN/A
Volume45.78K
Average Volume (3M)270.30K
Market Cap
$3.91B
Enterprise Value$4.50B
Total Cash (Recent Filing)$288.33M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)83.2
Beta0.75
Next Earnings
Aug 10, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.87
Shares Outstanding24,993,586
10 Day Avg. Volume234,095
30 Day Avg. Volume270,295
Financial Highlights & Ratios
PEG Ratio-47.74
Price to Book (P/B)1.66
Price to Sales (P/S)1.58
P/FCF Ratio38.29
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda17.13
Forecast
1Y Price Target
$165.50Price Target Upside9.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)8.17
Revenue Forecast (FY)$2.17B
Bulls Say, Bears Say
Bulls Say
Consumable Recurring Revenue ModelThe business sells single-use infusion and vascular consumables, creating high-frequency repeat purchases and predictable reorder patterns. Structural stickiness from hospital standardization on connectors and pump platforms supports steady recurring revenue and durable cash conversion over months.
Infusion Systems Momentum And Regulatory ProgressRecord pump sales plus recent FDA software approval and multiple 510(k) clearances signal durable product-market fit and an expanding attach-rate opportunity for consumables. Regulatory progress reduces clearance risk and supports long-term platform adoption and recurring aftermarket revenue.
Improving Cash Flow And Balance Sheet ProgressPositive operating and free cash flow alongside falling leverage provide financial flexibility to fund integration, R&D, and debt reduction. Management's FCF target and stated deleveraging plan support sustainable investment and lower solvency risk over the coming months.
Bears Say
Reported Revenue Decline From DeconsolidationThe mid‑2025 deconsolidation materially reduced reported top-line and complicates comparability, masking underlying organic trends. Reliance on JV structuring and one-off accounting shifts can create persistent headline volatility and make near-term revenue guidance harder to interpret.
Thin Profitability And Volatile Earnings HistoryAlthough profitability has returned, margins remain thin versus historical levels and earnings have been inconsistent. Low net margins and prior loss years limit the firm's ability to absorb shocks, constrain reinvestment potential, and raise execution risk over the medium term.
Tariff, Logistics And Regulatory Timing RisksPersistent tariff and freight cost uncertainty and incremental FDA testing create structural margin and timing risks. Higher recurring trade costs and delayed hardware clearances can compress future gross margins and postpone attach-rate gains from new pumps, affecting multi-month revenue realization.
ICU Medical News
ICUI FAQ
What was Icu Medical’s price range in the past 12 months?
Icu Medical lowest stock price was $107.00 and its highest was $162.18 in the past 12 months.
What is Icu Medical’s market cap?
Icu Medical’s market cap is $3.91B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were Icu Medical’s earnings last quarter?
Icu Medical released its earnings results on May 07, 2026. The company reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.752 by $0.218.
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 1.91.
How many shares outstanding does Icu Medical have?
Icu Medical has 24,993,586 shares outstanding.
What happened to Icu Medical’s price movement after its last earnings report?
Icu Medical reported an EPS of $1.97 in its last earnings report, beating expectations of $1.752. Following the earnings report the stock price went up 2.73%.
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in ICUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.50 (9.13% Upside)
$165.50 (9.13% Upside)
Hedge Fund Trend
Decreased
By 53.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $882.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.37%
12-Months-Change
Fundamentals
Return on Equity
2.19%
Trailing 12-Months
Asset Growth
-4.08%
Trailing 12-Months
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
ICUI Company Deck
ICUI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call framed a company with healthy operational momentum in its core businesses: record Infusion Systems results, modest consumables growth, gross margin expansion, and EPS improvement (+15%). Offsetting these positives are transitory but material items that affect reported results and near-term risk: the IV Solutions deconsolidation lowering reported revenue, tariff and logistics cost pressures (potential ~$10M headwind), ongoing integration/remediation spend, and timing risk from additional FDA testing for new pump hardware. Management reiterated full-year guidance and articulated paths to offset macro and trade headwinds through tariff benefits and operational efficiencies, signaling confidence in achieving targets.View all ICUI earnings summariesICUI Stock 12 Month Forecast
Average Price Target
$165.50
▲(9.13% Upside)
Technical Analysis
Ownership Overview
1.92% Insiders
39.31% Mutual Funds
1.38% Other Institutional Investors
28.49% Public Companies and
Individual Investors